Learn Mode

AUPH - Aurinia Pharmaceuticals Inc

15

$14.27

-$0.33 (-2.260%)

At market close

$14.28

$0.01 (0.077%)

After Hours 3/27/26, 9:50 PM

4.14/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

AUPH

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$1.90B

Industry

Biotechnology

EPS (TTM)

$2.08

P/E (TTM)

6.61

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

6.70

P/B

3.26

Diluted Shares

137.92M

Ex-Dividend

--

Next Earnings

05-11

Forward P/E

16.62

Payout Ratio

--

P/FCF (TTM)

14.01

FCF Yield

7.14%

Earnings Yield

15.14%

52 Week Range

Score Card

Explore Scores Tab

4.14

Good

Aurinia Pharmaceuticals Inc has grown revenue at 20.38% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

3.00

Average

Management

3.00

Average

Growth

4.00

Good

Profitability

2.00

Bad

Fin. Health

1.00

Very Bad

Dividends

--

--

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form SCHEDULE 13D/A

Unknown Form Type

Filed on 2026-03-25 16:15:07

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-23 08:03:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:25:53

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 17:35:12

Form SCHEDULE 13D/A

Unknown Form Type

Filed on 2026-03-03 17:30:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:14:36

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:14:15

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:13:51

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:13:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:12:57

Form 10-K

Annual financials report pursuant to Section 13 or 15(d)

Filed on 2026-02-26 06:06:24

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-02-26 06:02:50

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$22.05

54.5%

Avg:

$17.05

19.5%

Low:

$13.13

-8.0%

(% change is relative to the current stock price: $14.27)

Analyst Recommendations

Go to Analyst Tab

3.92

Good

23%

Strong Buy (3)

46%

Buy (6)

31%

Hold (4)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.auriniapharma.com
Address
#140, 14315 - 118 Avenue, Edmonton ALBERTA, CA
SEC Reports
https://sec.gov/edgar/browse/?CIK=1600620

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

IPO Date

2001-07-16

Industry

Biotechnology

Total Employees

300

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences